Tirzepatide: A Research Overview of the Dual Agonist
Tirzepatide is a 39-amino-acid synthetic peptide designed to act at two incretin receptors at once: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Developed by engineering GLP-1 activity into the sequence of native GIP, it has become one of the most studied dual-agonist scaffolds in metabolic research. This overview summarises what the published preclinical and structural literature says about its design, receptor pharmacology and signalling behaviour, and how Tirzepatide is used as a reference compound in the laboratory.
Background: why a dual incretin agonist?
The incretin system describes gut-derived hormones released after nutrient intake that potentiate insulin secretion from pancreatic islets. Two hormones dominate this system: GLP-1, secreted by intestinal L-cells, and GIP, secreted by K-cells of the proximal small intestine. Single-agonist research has historically focused on GLP-1R, producing analogues such as semaglutide. GIP, by contrast, was long considered a weaker research target, in part because its signalling appeared blunted in some disease models.
The rationale for combining both activities is that the two receptors are expressed in overlapping but distinct tissues, including pancreatic islets and regions of the central nervous system, and may contribute complementary effects on insulin secretion, food intake and energy balance in animal models. Tirzepatide was developed to test that hypothesis within a single molecule. Coskun and colleagues described its discovery and early characterisation in Molecular Metabolism (2018), reporting that in mice the compound improved glucose tolerance, stimulated glucose-dependent insulin secretion through both receptors, and with chronic dosing reduced body weight and food intake to a greater extent than a selective GLP-1 receptor agonist.
Molecular structure and design
Tirzepatide is a linear 39-residue peptide built on the native GIP backbone, with modifications that confer GLP-1 receptor activity and extend its half-life. A C20 fatty diacid moiety is attached to a lysine residue (Lys20) through a linker. This lipid group binds serum albumin, a strategy also used in other long-acting peptide analogues, and slows clearance in the experimental setting. Albumin binding also has a measurable effect in vitro: Willard et al. (JCI Insight, 2020) found that adding 1% human serum albumin to cAMP assays right-shifted tirzepatide's potency approximately 26-fold at GIPR and 81-fold at GLP-1R, an important consideration when comparing assay conditions across laboratories.
Cryo-electron microscopy has resolved how the peptide engages both receptors. Sun et al. (PNAS, 2022) reported structures of GIPR bound to GIP (3.2 Å) and to tirzepatide (3.1 Å), and of GLP-1R bound to tirzepatide (2.9 Å). In both receptors tirzepatide adopts an α-helical conformation with its N-terminus inserted deep into the transmembrane core, as native ligands do. The lipid moiety and the C-terminal residues 33–39 were not resolved, consistent with their flexibility.
Receptor pharmacology: an imbalanced agonist
A defining feature reported in the literature is that tirzepatide does not engage the two receptors equally. In the Willard et al. characterisation, its cAMP potency at GIPR was equivalent to native GIP (EC50 1.01 nM versus 0.888 nM), and its binding affinity at GIPR matched that of GIP. At GLP-1R, however, binding affinity was roughly fivefold weaker than native GLP-1, and cAMP potency was approximately 18- to 20-fold lower (EC50 6.54 nM versus 0.366 nM). The authors therefore described tirzepatide as an “imbalanced” dual agonist, with a clear preference for GIPR.
The structural work offers a plausible explanation. Sun et al. observed that Thr7 of tirzepatide (an isoleucine in native GIP) forms a hydrogen bond with Arg190 of GIPR, which may support high-affinity binding at that receptor. At GLP-1R, the bulkier N-terminal Tyr1 (compared with His7 in GLP-1) displaces Trp306 and disrupts polar contacts between transmembrane helix 5 and extracellular loop 3. Substituting Tyr1 with histidine in a lipid-free analogue weakened binding at GIPR about 20-fold while restoring GLP-1R potency to that of GLP-1, illustrating how a single residue shapes the balance between the two targets. Removing the C20 lipid also increased affinity at both receptors in that study, indicating that the fatty diacid carries a cost in receptor engagement that is offset by its pharmacokinetic benefit.
Biased signalling at GLP-1R
G protein-coupled receptors can signal through more than one intracellular route, and ligands can favour one route over another, a property called biased agonism. Two routes matter here: Gαs-mediated cAMP production, and recruitment of β-arrestins, which is associated with receptor desensitisation and internalisation.
At GIPR, Willard et al. found tirzepatide behaved like native GIP, acting as a full agonist for both cAMP generation and β-arrestin-2 recruitment (EC50 2.34 nM versus 1.58 nM for GIP). At GLP-1R the picture differed. Tirzepatide was a partial agonist for Gαs activation (approximately 51% efficacy in GTPγS assays) and produced less than 10% of the maximal β-arrestin-2 response, a pattern the authors characterised as bias toward cAMP over β-arrestin. Receptor internalisation followed the same trend: tirzepatide reached only about 40–44% of the maximal GLP-1R internalisation seen with GLP-1, while at GIPR its internalisation matched GIP.
Sun et al. reached a consistent conclusion using different readouts. Tirzepatide was a partial Gs agonist at GLP-1R with weak β-arrestin and GRK2 recruitment, and caused markedly less internalisation than GLP-1 in islets (intracellular fluorescence 46.0 versus 104.5, in the units reported). Removing the lipid and restoring His at position 1 pushed the analogue toward full efficacy in GRK2 and β-arrestin recruitment, which suggests that the lipid and the N-terminal residue together produce the observed bias.
A mouse islet experiment from the same Willard study is informative. Islets from mice lacking β-arrestin-1 in β-cells secreted more insulin than controls when stimulated with GLP-1, showing that β-arrestin-1 normally limits the native hormone's effect. No genotype difference was seen with GIP or with tirzepatide, and with GIPR blocked, tirzepatide's insulin response was equivalent in both genotypes. This supports the interpretation that reduced β-arrestin engagement at GLP-1R allows tirzepatide to avoid a brake that constrains GLP-1 itself in this model. Whether this property matters beyond the in vitro and ex vivo systems studied remains an open research question.
Receptor occupancy and assay considerations
Because tirzepatide binds albumin heavily, free-ligand concentrations in biological matrices differ substantially from nominal concentrations. Willard et al. used albumin-adjusted potencies to model relative receptor occupancy and predicted substantially higher occupancy at GIPR than at GLP-1R across the exposure range they considered. Whatever the precise figures, the practical lesson for bench work is that potency values depend strongly on albumin content, cell receptor density and assay format. Experiments intended to compare tirzepatide with selective GLP-1R or GIPR ligands should therefore control for these variables, and results should be reported with the buffer composition specified.
Position among related research compounds
Tirzepatide sits between selective GLP-1R agonists and newer multi-receptor candidates. A fuller comparison with the triple-agonist scaffold, which adds glucagon receptor activity, is available in our article Retatrutide vs Tirzepatide: receptor targets compared. For readers interested in how single-agonist GLP-1 analogues are engineered, see also the overview of semaglutide’s design on this blog.
Laboratory handling and quality considerations
Tirzepatide is supplied for research as a lyophilised powder. Its lipidation makes it more hydrophobic and more prone to adsorption on plastic surfaces than unmodified peptides, so low-binding labware and careful documentation of vehicle and diluent are advisable. Lyophilised material should be stored cold and protected from moisture and light, and reconstituted solutions handled aseptically and used promptly; general principles are covered in our guide to peptide storage and handling. Because lipidated peptides can carry closely related impurities, such as deletion sequences or incompletely acylated species, independent analytical confirmation of identity and purity is particularly valuable. Batch data for PureX compounds, including HPLC and mass spectrometry results, are published on the Lab Results page.
Open questions in the literature
Several questions remain active areas of preclinical investigation. These include the relative contribution of GIPR versus GLP-1R signalling to the effects seen in animal models, whether GIPR agonism and antagonism can paradoxically converge on similar outcomes, how biased signalling shapes receptor desensitisation over prolonged exposure, and which tissues and neuronal populations mediate the observed effects on food intake in rodents. Structural data now give researchers a concrete framework for designing analogues that tune the balance between receptors, and this is likely to remain a productive area of peptide pharmacology.
References
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18.
Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA. 2022;119(13):e2116506119.
Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.